LMF
PRTK

LMR Master Fund’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

LMR Master Fund’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-1,881
Closed -$68K – 444
2013
Q2 		$68K Buy
+1,881
New +$80.6K 0.01% 434

Other funds holding PRTK

RAM
Roumell Asset Management Chevy Chase, Maryland $53.3M AUM 8.91% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
LOM
Loeb Offshore Management New York $547M AUM 50.11% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

LMR Master Fund's PRTK Position: Q3 2013 in Review

LMR Master Fund sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2013, closing a stake of 1,881 shares — an estimated $68K sold.

LMR Master Fund first reported a position in PRTK in Q2 2013 and held it in 1 quarter. The position peaked at $68K in Q2 2013. 42 funds tracked by Wall St. Rank hold PRTK as of Q3 2013.

  • LMR Master Fund reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2013 after selling out during the quarter.
  • LMR Master Fund sold 1,881 Paratek Pharmaceuticals, Inc. shares in Q3 2013, an estimated $68K.
  • LMR Master Fund first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2013 and held it in 1 quarter.
  • LMR Master Fund's Paratek Pharmaceuticals, Inc. position peaked at $68K in Q2 2013.
  • 42 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2013.

Based on LMR Master Fund's 13F filing for Q3 2013, filed 14 Nov 2013.